Sugi Predict

Sugi Predict / Compounds / SCHEMBL6170399

SCHEMBL6170399

SCHEMBL6170399

Cc1nc2ccc(C(=O)O)cc2n1C(C(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ ACSS2 Q9NR19 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ HPGD P15428 2/20 0.40
▸ THRB P10828 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ CES2 O00748 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ KDM5A P29375 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169714 0.86 PDE2A (0.51) SMN1; SMN2ALDH1A1KDM4EL3MBTL1MAPT
SCHEMBL6169568 0.81 HSD17B10 (0.46) HSD17B10SMN1; SMN2ACSS2HPGDLMNA
SCHEMBL1179934 0.79 PPARG (0.51) HSD17B10ACSS2ALDH1A1KDM4EL3MBTL1
SCHEMBL13666576 0.73 HSD17B10 (0.79) HSD17B10SMN1; SMN2HTTTDP1FGFR1
SCHEMBL18247596 0.72 TDP1 (0.53) HSD17B10SMN1; SMN2HTTTDP1FGFR1
SCHEMBL8556792 0.71 ACSS2 (0.48) HSD17B10SMN1; SMN2ACSS2HTTFGFR1
SCHEMBL6169195 0.70 TNF (0.62) HSD17B10ACSS2RAB9A
SCHEMBL6169496 0.70 PDE2A (0.51) SMN1; SMN2ACSS2ALDH1A1KDM4EHPGD
SCHEMBL15540769 0.69 MEN1 (0.49) HSD17B10KDM4ELMNA
SCHEMBL6170393 0.69 HDAC1 (0.57) HSD17B10ACSS2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 — — EP disclosed
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives OSI PHARMACEUTICALS, INC. 2002-06-27 — — US disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 — — US disclosed
US-6348032-B1 POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. CELL PATHWAYS, INC. 2002-02-19 — — US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 — — US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives MKI67, CCNI, TMBIM6 HSD17B10 1746/4885SMN1; SMN2 4367/4885ACSS2 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.